Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Core Insights - Axsome Therapeutics, Inc. announced that the EMERGE Phase 3 trial of Symbravo met its primary endpoint, showing a statistically significant greater migraine treatment response compared to oral CGRP inhibitors [1][2] Group 1: Trial Results - Symbravo demonstrated a treatment response measured by the Migraine Treatment Optimization Questionnaire (mTOQ-4) with scores of 5.2 versus 2.8 for oral CGRP inhibitors, achieving statistical significance (p<0.001) [1] - The trial indicated that Symbravo rapidly and substantially improved migraine pain and bothersome symptoms [2] Group 2: Patient Outcomes - 47.9% of patients reported pain freedom within 2 hours after treatment with Symbravo, compared to only 1.0% for oral CGRP inhibitors [3] - Sustained relief of migraine pain for at least 24 hours was reported by 47.9% of patients using Symbravo, versus 16.7% for oral CGRP inhibitors [3] - 51.0% of patients were able to quickly return to normal activities after taking Symbravo, compared to 11.5% for oral CGRP inhibitors [3] - 63.5% of patients felt comfortable enough with Symbravo to plan daily activities, compared to 26.0% for oral CGRP inhibitors [3]